New England Research & Management Inc. Acquires 3,120 Shares of Danaher Corporation $DHR

Posted by Brian Himes on Oct 17th, 2026

New England Research & Management Inc. acquired a new position in shares of Danaher Corporation (NYSE:DHR – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 3,120 shares of the conglomerate’s stock, valued at approximately $691,000.

Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Danaher in the second quarter valued at about $10,492,520,000. Jupiter Topco LLC purchased a new position in Danaher during the second quarter worth about $1,456,317,000. Generation Investment Management LLP purchased a new position in Danaher during the second quarter worth about $1,287,949,000. Bank of America Corp DE bought a new stake in Danaher in the 2nd quarter worth about $993,846,000. Finally, Legal & General Group Plc bought a new stake in Danaher in the 2nd quarter worth about $801,056,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE:DHR traded down $2.63 during midday trading on Friday, reaching $228.87. The company had a trading volume of 3,516,366 shares, compared to its average volume of 4,667,069. The stock has a market cap of $160.89 billion, a P/E ratio of 40.65, a P/E/G ratio of 2.91 and a beta of 0.76. The company’s 50 day moving average price is $214.04 and its 200 day moving average price is $195.97. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the company posted $0.77 earnings per share. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. TD Cowen increased their price objective on shares of Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday. UBS Group initiated coverage on Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price on the stock. The Goldman Sachs Group upped their target price on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Stifel Nicolaus decreased their price target on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Check Out Our Latest Research Report on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.